Iovance TIL Appeal Seen Luring Potential Buyers
Media Reports Say US Biotech Is In Active M&A Talks
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.
You may also be interested in...
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.